Miniatura

Fitxers

907524.pdf (1.18 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2025-12

Llicència de publicació

cc-by-nc-nd (c) European Society for Medical Oncology, CH, 2025
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/227020

Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.esmoop.2025.105922

Resum

Background: Everolimus or streptozotocin plus 5-fluorouracil (STZ/5-FU) are approved treatments for patients with pancreatic neuroendocrine tumors (panNETs). The SEQTOR trial aimed to assess the optimal treatment sequence. Patients and methods: SEQTOR was an international, open-label, randomized, crossover, phase III trial that recruited adults with unresectable or metastatic, advanced, well-differentiated panNET. Patients received 10 mg/day of everolimus followed upon progression by STZ/5-FU; or the reverse sequence. The primary endpoint was the 35-month progression-free survival (PFS) rate after first- and second-line treatment; however, due to slow accrual and longer survival, it was changed to the 12-month PFS rate following first-line treatment (12-mPFS1). Results: Patients were randomized to everolimus (n = 72) or STZ/5-FU (n = 69) first. The 12-mPFS1 was 71.4% [95% confidence interval (CI) 59.4% to 81.6%] and 61.8% (95% CI 49.2% to 73.3%) (odds ratio 0.65, 95% CI 0.32-1.32) with a median PFS1 of 19.4 versus 22.7 months for everolimus and STZ/5-FU, respectively. STZ/5-FU achieved a significantly higher overall response rate in first-line (11.6% versus 30.3%, P = 0.012) and second-line (30.6% versus 9.1%, P = 0.072) treatments. No differences were shown in overall survival (median 61.7 versus 50.6 months in everolimus first and STZ/5-FU first, respectively; hazard ratio 1.43, 95% CI 0.86-2.37). Discontinuations of everolimus were more frequent. Conclusion: STZ/5-FU and everolimus were not statistically different in PFS rates, but STZ/5-FU achieved higher response rates. Keywords: 5-fluorouracil; advanced pancreatic neuroendocrine neoplasm; everolimus; panNET; sequential strategy; streptozotocin.

Matèries

Estreptomicina

Matèries (anglès)

Streptomycin

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

DE VOS-GEELEN, J., VENERITO, Marino, VON-WERDER, Alezander, JANN, Henning, RINKE, Anja, SMITH, D., HÖRSCH, D., STARLING, Naureen, RUSZNIEWSKI, Philippe, BAUDIN, Eric, METGES, J.-p., CAROLI-BOSC, F.-x., REED, N.s., MANZANO, José luis, SCHRADER, J., MARTÍN, M., NAVARRO PEREZ, Valentin, SCARPA, A., VALENTÍ, Víctor, LAWLOR, R.t., HERNANDO, Jorge, RAGULAN, C., COLAO, A.m., PS, H., VESTERMARK, Lene, SADANANDAM, A., CARNAGHI, Carlo, KNIGGE, U.p., CAPDEVILA, Jaume, TAFUTO, Salvatore, KROGH, M., TEULÉ-VEGA, Àlex, GARCIA CARBONERO, Rocio, KLÜMPEN, H.-j., CREMER, B., SEVILLA, I., ERIKSSON, B., TABAKSBLAT, E., CARMONA BAYONAS, Alberto, SALAZAR SOLER, Ramón, JIMÉNEZ FONSECA, Paula, BENAVENT VIÑUALES, Marta. Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial. _ESMO Open_. 2025. Vol. 12. [consulta: 22 de febrer de 2026]. ISSN: 2059-7029. [Disponible a: https://hdl.handle.net/2445/227020]

Exportar metadades

JSON - METS

Compartir registre